Artificial Limbs
Methodology & AI Transparency ⓘ
Artificial Limbs Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: People can lose all or part of an arm or leg for a number of reasons.
- 2 Real-world patient consensus: Clinical coding for Artificial Limbs uses ICD-10 R73.9 across Diabetes & Glucose specialty care.
- 3 Typical cash cost range: Primary evaluation for Artificial Limbs incorporates continuous glucose monitoring in Artificial Limbs (R73.9: (CGM) glycemic variability) and symptom diary review.
- 4 Top reported side effects / signs: Key Diabetes & Glucose biomarkers for Artificial Limbs (R73.9): CGM Time-in-Range (70–140 in Artificial Limbs (R73.9: mg/dL)) & Hemoglobin A1c (HbA1c) [Artificial Limbs R73.9] (4.8% – 5.6% (< 6.5% clinical target) (R73.9)).
Ask our AI Specialists anything about Artificial Limbs
What Is Artificial Limbs?
People can lose all or part of an arm or leg for a number of reasons. Common ones include: Circulation problems from atherosclerosis or diabetes. They may cause you to need an amputation . Traumatic injuries, including from traffic accidents and military combat Cancer Birth defects If you are missing an arm or leg, an artificial limb can sometimes replace it. The device, which is called a prosthesis, can help you to perform daily activities such as walking, eating, or dressing. Some artificial limbs let you function nearly as well as before.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Artificial Limbs (R73.9, Diabetes & Glucose) reflects advanced glycation end-product in Artificial Limbs (R73.9: microvascular injury). Cross-referenced with NIH MeSH (Artificial Limbs), longitudinal control is benchmarked via CGM Time-in-Range (70–140 in Artificial Limbs (R73.9: mg/dL)).
Common Symptoms & Clinical Signs
- • Circulation problems from atherosclerosis or diabetes. They may cause you to need an amputation
- • Traumatic injuries, including from traffic accidents and military combat
- • Presentation of Artificial Limbs (R73.9): elevated fasting blood in Artificial Limbs (R73.9: glucose or post-meal)
- • Secondary Artificial Limbs clinical sign: increased thirst [Artificial Limbs R73.9]
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Artificial Limbs Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R73.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: CGM Time-in-Range (70–140 in Artificial Limbs (R73.9: mg/dL)) | > 85% (R73.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hemoglobin A1c (HbA1c) [Artificial Limbs R73.9] | 4.8% – 5.6% (< 6.5% clinical target) (R73.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Artificial Limbs R73.9] | 75 – 95 mg/dL (R73.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Artificial Limbs
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Lensmate Preservative-Free Artificial Tears (Lubricant Eye Drops) Lensmate Preservative-Free Artificial Tears • RxCUI 359634 | Non-Standardized Chemical Allergen | 82% | $0.3584 | $ 34.31 /mo |
| Artificial Tears (Polyvinyl Alcohol, Povidone) Artificial Tears • RxCUI 598050 | Over-the-Counter Clinical Monograph | 90% | $0.3521 | $ 33.85 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Artificial Limbs)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Association between combined treatment with SGLT2 inhibitors and metformin for: What a 19,500-Participant Study Found SGLT2is and metformin combination therapy did not influence fracture risk compared with metformin single-drug treatment or other comparators in patients with T2DM. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA • 2020-12-15 • Meta-Analysis | N = 19,500 | 94/100 | PMID 32780153 ↗ |
| New Insights on Exenatide once weekly plus dapagliflozin once daily versus exenatide or: What a 695-Participant Study Found Co-initiation of exenatide and dapagliflozin improved various glycaemic measures and heart and blood vessel risk factors in patients with type 2 diabetes inadequately controlled by metformin single-drug treatment. The lancet. Diabetes & endocrinology • 2016-12-15 • Phase III Randomized Trial | N = 695 | 93/100 | PMID 27651331 ↗ |
| Can This Approach Help? Inside the Latest Research on Artificial Intelligence Analysis of Endoscopy Outperforms Conventional Endoscopic In 387 subjects, among endoscopically active subjects (MES 2, 3), the CDS was lower in those achieving PMS symptomatic full symptom relief (83.8 vs 186.9, P < 0.0001). The American journal of gastroenterology • 2026-04-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41247057 ↗ |
| Can This Approach Help? Inside the Latest Research on Kidney blood pressure and heart rate effects of the SGLT2 inhibitor dapagliflozin Beyond glucose control, SGLT2i reduce mGFR and filtration fraction in type 2 diabetes. Kidney international • 2020-01-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 31791665 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of saxagliptin in combination with metformin as initial Saxagliptin 5 mg plus metformin significantly improved glycaemic control compared with either single-drug treatment in treatment-naïve Chinese patients with type 2 diabetes, and was well tolerated. Diabetes, obesity & metabolism • 2018-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 28926170 ↗ |
Artificial Limbs Patient Community & “People Like Me” Threads
Filter Artificial Limbs community threads and patient logs by age, biological sex, dosage, and treatment duration.
Tracking CGM Time-in-Range (70–140 in Artificial Limbs (R73.9: mg/dL)) every 12 weeks for Artificial Limbs: what lab cadence worked best?
FDA/PubMed Clinical Context Note: Clinical guidelines across Type 1 & Type 2 Diabetes (Artificial Limbs, ICD-10-CM R73.9) generally pair 8-to-12-week repeat biomarker verification (CGM Time-in-Range (70–140 in Artificial Limbs (R73.9: mg/dL)): > 85% (R73.9)) with symptom review so steady-state physiological response is captured accurately.
After being diagnosed with Artificial Limbs (ICD-10 R73.9), my clinician and I set a goal around CGM Time-in-Range (70–140 in Artificial Limbs (R73.9: mg/dL)) (> 85% (R73.9)) before escalating medication doses. For others managing diabetes & glucose markers, did quarterly bloodwork catch changes early enough without over-testing?
12-week intervals worked really well for tracking CGM Time-in-Range (70–140 in Artificial Limbs (R73.9: mg/dL)). Using the same morning fasting draw window each quarter eliminated day-to-day noise so my doctor could adjust cleanly.
Ordering CGM Time-in-Range (70–140 in Artificial Limbs (R73.9: mg/dL)) alongside standard preventive labs prior to my follow-up visit saved an extra co-pay and kept our appointment focused on actual trend lines.